SRZN — Surrozen, Inc.

Surrozen (SRZN) Q4 2022 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash, cash equivalents, and marketable securities totaled approximately $76 million at the end of 2022.
• The company expects its cash runway to extend into the second half of 2024, allowing for the achievement of multiple key milestones.
• A restructuring effort is anticipated to reduce operating expenses by approximately 15% in 2023 compared to 2022.

2. Strategic Updates and Business Highlights

• Surrozen is focused on leveraging its proprietary Wnt pathway technology to develop tissue-selective antibodies aimed at regenerating tissue in various diseases.
• Key clinical candidates include:
  • SZN-043: Targeting severe alcoholic hepatitis, currently in Phase I trials with the first patient enrolled.
  • SZN-1326: Targeting inflammatory bowel disease (IBD), also in Phase I trials, with a voluntary pause in enrollment due to observed liver enzyme elevations.
• A partnership with Boehringer Ingelheim was established for SZN-413, a Wnt agonist for retinal diseases, with a potential milestone payment of $10 million expected by year-end 2023.
• The company is advancing its research programs in corneal regeneration and severe dry eye, with plans to optimize and finalize lead molecules for development in 2023.

3. Forward Guidance and Outlook

• Surrozen anticipates having data from the Phase I study of SZN-043 in chronic liver disease patients by the end of 2023, with a Phase Ib trial in severe alcoholic hepatitis expected to start in 2024.
• For SZN-1326, data from the Phase I study in healthy volunteers is also expected by year-end 2023, with a Phase Ib trial in ulcerative colitis patients planned for 2024.
• The company aims to identify additional development candidates and potentially partner programs in the near future.

4. Bad News, Challenges, or Points of Concern

• The company reported adverse events related to transaminase elevations in both SZN-043 and SZN-1326, leading to a voluntary pause in the SZN-1326 trial for further evaluation.
• Concerns were raised regarding the safety of these candidates in hepatically impaired patients, with no specific mitigation strategies identified at this time.
• The need for a careful approach to dosing strategies was emphasized due to the unexpected liver-related adverse events observed in clinical trials.

5. Notable Q&A Insights

• Management clarified that the Phase I study for SZN-043 is targeting chronic liver disease patients, which may include those with fibrosis but not necessarily cirrhosis.
• The half-life of SZN-1326 is approximately five days, with potential dosing regimens being considered for every other week or less frequent based on biological effects.
• The company is investigating the mechanisms behind the observed liver enzyme elevations, suggesting they may be linked to the regenerative effects of the Wnt pathway rather than direct toxicity.
• Management expressed confidence in the therapeutic potential of both candidates, despite the observed adverse events, citing robust preclinical data supporting their efficacy.

This summary encapsulates the key points from Surrozen's Q4 2022 earnings call, highlighting financial metrics, strategic initiatives, forward guidance, challenges faced, and insights from the Q&A session.